Department of Clinical and Experimental Medicine, University of Catania, Via S. Sofia 78, 95123 Catania, Italy.
Nutrients. 2020 Sep 28;12(10):2967. doi: 10.3390/nu12102967.
Obesity has become an increasingly worrisome reality. A very-low-calorie ketogenic diet (VLCKD) represents a promising option by which to achieve significant weight loss. This study sought to evaluate the effectiveness of VLCKD on metabolic parameters and hormonal profiles of obese male patients.
We enrolled 40 overweight/obese men who consumed VLCKD for at least eight weeks. Body weight, waist circumference, fasting glucose, insulin, total cholesterol, high-density lipoprotein, triglycerides, creatinine, uric acid, aspartate aminotransferase, alanine aminotransferase, vitamin D, luteinizing hormone (LH), total testosterone (TT), and prostate-specific antigen (PSA) were calculated before and after VLCKD consumption. We additionally determined the homeostasis model assessment index and low-density lipoprotein (LDL) values.
After VLCKD (13.5 ± 0.83 weeks), the mean body weight loss was 21.05 ± 1.44 kg; the glucose homeostasis and lipid profile were improved significantly; serum vitamin D, LH, and TT levels were increased and the PSA levels were decreased significantly as compared with pretreatment values. These results are of interest since obesity can lead to hypogonadism and in turn, testosterone deficiency is associated with impaired glucose homeostasis, metabolic syndrome, and diabetes mellitus. Moreover, a close relationship between obesity, insulin resistance, and/or hyperinsulinemia and increased prostate volume has been reported, with a consequent greater risk of developing lower urinary tract symptoms.
VLCKD is an effective tool against obesity and could be a noninvasive, rapid, and valid means to treat obese patients with metabolic hypogonadism and lower urinary tract symptoms.
肥胖已成为一个日益令人担忧的现实。极低卡路里生酮饮食(VLCKD)是一种很有前途的减肥方法。本研究旨在评估 VLCKD 对肥胖男性患者代谢参数和激素谱的影响。
我们招募了 40 名超重/肥胖男性,他们至少连续 8 周食用 VLCKD。在食用 VLCKD 前后,计算体重、腰围、空腹血糖、胰岛素、总胆固醇、高密度脂蛋白、甘油三酯、肌酐、尿酸、天门冬氨酸氨基转移酶、丙氨酸氨基转移酶、维生素 D、黄体生成素(LH)、总睾酮(TT)和前列腺特异性抗原(PSA)。我们还测定了稳态模型评估指数和低密度脂蛋白(LDL)值。
在 VLCKD 治疗后(13.5±0.83 周),体重平均下降 21.05±1.44kg;葡萄糖代谢和血脂谱显著改善;血清维生素 D、LH 和 TT 水平升高,PSA 水平显著下降,与治疗前相比差异有统计学意义。这些结果很有趣,因为肥胖会导致性腺功能减退,而睾丸激素缺乏与葡萄糖代谢紊乱、代谢综合征和糖尿病有关。此外,已有研究报道肥胖、胰岛素抵抗和/或高胰岛素血症与前列腺体积增大之间存在密切关系,从而增加了下尿路症状的发病风险。
VLCKD 是对抗肥胖的有效手段,也可能是非侵入性的、快速的、有效的方法来治疗肥胖伴代谢性性腺功能减退和下尿路症状的患者。